Ganghuo Kanggan Decoction in Influenza: Integrating Network Pharmacology and In Vivo Pharmacological Evaluation

Author:

Lai Yanni,Zhang Qiong,Long Haishan,Han Tiantian,Li Geng,Zhan Shaofeng,Li Yiwei,Li Zonghui,Jiang Yong,Liu Xiaohong

Abstract

Background: Ganghuo Kanggan decoction (GHKGD) is a clinical experience prescription used for the treatment of viral pneumonia in the Lingnan area of China, and its clinical effect is remarkable. However, the mechanism of GHKGD in influenza is still unclear.Objective: To predict the active components and signaling pathway of GHKGD and to explore its therapeutic mechanism in influenza and to verified it in vivo using network pharmacology.Methods: The potential active components and therapeutic targets of GHKGD in the treatment of influenza were hypothesized through a series of network pharmacological strategies, including compound screening, target prediction and pathway enrichment analysis. Based on the target network and enrichment results, a mouse model of influenza A virus (IAV) infection was established to evaluate the therapeutic effect of GHKGD on influenza and to verify the possible molecular mechanism predicted by network pharmacology.Results: A total of 116 candidate active compounds and 17 potential targets were identified. The results of the potential target enrichment analysis suggested GHKGD may involve the RLR signaling pathway to reduce inflammation in the lungs. In vivo experiments showed that GHKGD had a protective effect on pneumonia caused by IAV-infected mice. Compared with the untreated group, the weight loss in the GHKGD group in the BALB/c mice decreased, and the inflammatory pathological changes in lung tissue were reduced (p < 0.05). The expression of NP protein and the virus titers in lung were significantly decreased (p < 0.05). The protein expression of RIG-I, NF-kB, and STAT1 and the level of MAVS and IRF3/7 mRNA were remarkably inhibited in GHKGD group (p < 0.05). After the treatment with GHKGD, the level of Th1 cytokines (IFN-γ, TNF-α, IL-2) was increased, while the expression of Th2 (IL-5, IL4) cytokines was reduced (p < 0.05).Conclusion: Through a network pharmacology strategy and in vivo experiments, the multi-target and multi-component pharmacological characteristics of GHKGD in the treatment of influenza were revealed, and regulation of the RLR signaling pathway during the anti-influenza process was confirmed. This study provides a theoretical basis for the research and development of new drugs from GHKGD.

Funder

National Natural Science Foundation of China

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference42 articles.

1. Animal models for the study of influenza pathogenesis and therapy;Barnard;Antivir. Res.,2009

2. Todesfälle durch Influenzapandemien in Deutschland 1918 bis 2009. Schätzwerte auf Basis der Literatur und ergänzende eigene Berechnungen [Influenza pandemic deaths in Germany from 1918 to 2009. Estimates based on literature and own calculations];Buchholz;Bundesgesundheitsblatt—Gesundheitsforsch.—Gesundheitsschutz,2016

3. Effects of Ganghuo Kanggan Decoction on viral pneumonia mice caused by H1N1 influenza virus;Chen;CJTCMP,2015

4. Host immune response to influenza A virus infection;Chen;Front. Immunol.,2018

5. The 2009 pandemic in Mexico: experience and lessons regarding national preparedness policies for seasonal and epidemic influenza. La pandemia de 2009 en México: experiencia y lecciones acerca de las políticas nacionales de preparación contra la influenza estacional y epidémica;Cordova-Villalobos;Gac. Med. Mex.,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3